Cogentix Medical (Cogentix Medical) Total Liabilities : $10.71 Mil (As of Dec. 2017)

View and export this data going back to 1992. Start your Free Trial

What is Cogentix Medical Total Liabilities?

Cogentix Medical's Total Liabilities for the quarter that ended in Dec. 2017 was $10.71 Mil.

Cogentix Medical's quarterly Total Liabilities increased from Jun. 2017 ($8.22 Mil) to Sep. 2017 ($10.42 Mil) and increased from Sep. 2017 ($10.42 Mil) to Dec. 2017 ($10.71 Mil).

Cogentix Medical's annual Total Liabilities declined from Mar. 2015 ($34.01 Mil) to Dec. 2016 ($10.14 Mil) but then increased from Dec. 2016 ($10.14 Mil) to Dec. 2017 ($10.71 Mil).

Cogentix Medical Total Liabilities Historical Data

The historical data trend for Cogentix Medical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cogentix Medical Total Liabilities Chart

Cogentix Medical Annual Data

Trend

Mar08

Mar09

Mar10

Mar11

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Total Liabilities

Get a 7-Day Free Trial

19.97

25.35

34.01

10.14

10.71

Cogentix Medical Quarterly Data
	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17
Total Liabilities	Get a 7-Day Free Trial															10.14	8.34	8.22	10.42	10.71

Cogentix Medical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cogentix Medical's Total Liabilities for the fiscal year that ended in Dec. 2017 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9.379	+	(0	+	0.478
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.586	+	0.265)
	=	10.71

Total Liabilities	=	Total Assets (A: Dec. 2017 )	-	Total Equity (A: Dec. 2017 )
	=	74.744	-	64.036
	=	10.71

Cogentix Medical's Total Liabilities for the quarter that ended in Dec. 2017 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9.379	+	(0	+	0.478
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.586	+	0.265)
	=	10.71

Total Liabilities	=	Total Assets (Q: Dec. 2017 )	-	Total Equity (Q: Dec. 2017 )
	=	74.744	-	64.036
	=	10.71

Cogentix Medical Total Liabilities Related Terms

Thank you for viewing the detailed overview of Cogentix Medical's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cogentix Medical (Cogentix Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cogentix Medical Inc (NAS:CGNT) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

5420 Feltl Road, Minnetonka, MN, USA, 55343

Website

http://www.cogentixmedical.com

Cogentix Medical Inc is a medical device company. The company designs, develops, manufactures and markets a robust line of high-performance fiberoptic and video endoscopy products under the PrimeSight brand that is used across multiple surgical specialties in diagnostic and treatment procedures. Cogentix offers the Urgent PC Neuromodulation System, a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB). It also develops Macroplastique an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence primarily resulting from intrinsic sphincter deficiency.

Executives

Nachum Shamir	director	12212 TECHNOLOGY BLVD, AUSTIN TX 78727
Brett Reynolds	officer: SVP, CFO, Treasurer	5000 W 36TH STREET, MINNEAPOLIS MN 55416
Kenneth A Samet	director	800 KING FARM BOULEVARD, 4TH FLOOR, ROCKVILLE MD 20850
Uri Geiger	director	221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Accelmed Growth Partners, L.p.	10 percent owner	6 HACHOSHLIM STREET, 6TH FLOOR, HERZLIYA PITUACH L3 4672406
Accelmed Growth Partners Management Ltd.	10 percent owner	6 HACHOCHLIM STREET, 6TH FLOOR, HERZLIYA PITUACH L3 4672406
Accelmed Growth Partners (gp), L.p.	10 percent owner	6 HACHOCHLIM STREET, 6TH FLOOR, HERZLIYA PITUACH L3 4672406
Accelmed Growth Partners (agp) Ltd	10 percent owner	6 HACHOCHLIM STREET, 6TH FLOOR, HERZLIYA PITUACH L3 4672406
Cheryl Pegus	director	40 RAMLAND ROAD, ORANGEBURG CA 10962
Kenneth H Paulus	director	5420 FELTL ROAD, MINNETONKA MN 55343
Sven Wehrwein	director
Kevin H Roche	director
David W Anderson	director	519 LYNMERE ROAD, BRYN MAWR PA 19010